Revolutionary nonviral vectors offer safer and more affordable gene delivery

The precision genetics medicine company Mediphage Bioceuticals has developed an innovative DNA ministrings platform for safe, effective, and accessible ex vivo (cell) and in vivo (gene) therapies, including chimeric antigen receptor T-cells (CAR-Ts), CRISPR/Cas, and pluripotent stem-cell therapeutic applications.

Go to the profile of Mediphage Bioceuticals
Nov 07, 2018
1
0
Page of
Go to the profile of Mediphage Bioceuticals

Mediphage Bioceuticals

Mediphage Bioceuticals is a genetic medicine company spun out of the University of Waterloo in Canada, focused on developing SAFE, EFFECTIVE, and ACCESSIBLE gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.

No comments yet.